德基科技控股(01301.HK):預計中期純利不少於800萬元 實現扭虧為盈
格隆匯7月12日丨德基科技控股(01301.HK)發佈公吿,集團預期截至2021年6月30日止6個月的收益將較去年同期增加約50%至60%。有關增幅主要歸因於經濟從2019冠狀病毒病疫情的影響中逐漸復甦,而令集團的銷售額增加。
集團預期將錄得截至2021年6月30日止6個月的公司擁有人應占淨溢利不少於人民幣800萬元,而去年同期的公司擁有人應占淨虧損約為人民幣2700萬元。由淨虧損轉為淨溢利的預期轉虧為盈主要歸因於收入確認增加;存貨減值撥備減少;並無物業、廠房及設備減值;以及金融資產減值虧損淨撥回減少而部份抵銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.